ClinicalTrials.gg
CompletedNCT00747149ADAPTUpdated Aug 31, 2011Results posted

A Diabetes Study to Treat A Population Previously Not at Target

A Phase 4 interventional study of Rosuvastatin in Type 2 Diabetes, sponsored by AstraZeneca. Completed at 84 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-31.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
598
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca — 13 open to participants now, 15 under way, 9 of them phase 3. Diabetes Mellitus, Type 2 · AstraZeneca.

Enrollment
54th of 280
598 · median 155
Started
2008
with 32 others
Phase 4
28 of 345
none open now
Registered
97th of 345
by date

Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 54th largest by enrollment of the 280 interventional ones that give a count, is one of 33 that started in 2008, is one of 28 in phase 4, and was the 97th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

13 of the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, or all of them as a file.
02

Study summary

This study will assess if customizing the start dose of rosuvastatin appropriate for the degree of LDL-C reduction required, would achieve LDL-C target of ≤ 2.0 mmol/L quickly with either no titration or just one titration step after 6 weeks of therapy in type 2 diabetic patients previously treated with another statin and not at LDL-C targets.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • diabetes
  • type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Type 2 diabetes
  • Previously treated with a commonly accepted start dose of a statin for the last 4 weeks prior to study entry
  • Fasting LDL-C concentration of > 2.0 mmol/L (and ≤ 5.0 mmol/L) (in the past 3 months)
  • History of serum TG level of ≤ 4.6 mmol/l (in the past 3 months)

Exclusion criteria

Exclusion Criteria:

  • If currently receiving therapy with any statin at a dose higher than listed
  • Rosuvastatin (current use)
  • Fibrates, niacin or resins that was not discontinued a minimum of 2 months prior to enrolment.
  • Type 1 diabetes; (HbA1c) > 9.0%
  • (ALT) or aspartate aminotransferase (AST) level ≥ 1.5 × (ULN) (in the past 2 months)
  • Resting diastolic or systolic blood pressure of > 95 mmHg or > 180 mmHg, respectively (in the past 2 months)
  • Unexplained serum creatine kinase (CK) level > 3 × ULN (in the past 2 months).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
598 participants (actual)

Study arms

  • Experimental
    Rosuvastatin 1

    titrated

    Drug: Rosuvastatin

  • Experimental
    Rosuvastatin 2

    Non-titrated

    Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Achieving Canadian Low Density Lipoprotein Cholesterol (LDL-C) Target Goals (i.e. LDL-C ≤ 2.0 mmol/L) After 12 Weeks of Rosuvastatin Therapy

    The number of subjects achieving Canadian Low density lipoprotein cholesterol (LDL-C) target goals (i.e. LDL-C ≤ 2.0 mmol/L) over the total number subjects treated after 12 weeks of rosuvastatin therapy multiplied by 100

    Time frame: 12 Weeks

Secondary outcomes

  1. Percentage of Subjects Achieving Total Cholesterol (TC)/ High-density Lipoprotein Cholesterol (HDLC) Ratio (i.e. TC/HDL < 4.0 mmol/L) at 6 and 12 Weeks of Treatment

    Proportion of subjects achieving total cholesterol (TC)/ High-density lipoprotein cholesterol (HDLC) ratio (i.e. TC/HDL \< 4.0 mmol/L) at 6 and 12 weeks of treatment

    Time frame: 6 and 12 Weeks

  2. Mean Percent Change in Total Cholesterol (TC), Low Density Lipoprotein Cholesterol (LDL-C), High-density Lipoprotein Cholesterol (HDLC) , TC/HDL-C Ratio, Non-HDL-C, Triglycerides and Apolipoprotein B (ApoB) /Apolipoprotein A1 (ApoA-1) Ratio

    Time frame: 6 and 12 Weeks

  3. Mean High Sensitivity C-reactive Protein (hsCRP) Value at Week 6 and 12

    Time frame: 6 and 12 Weeks

  4. Incidence of Adverse Events and Abnormal Laboratory Values After 12 Weeks of Therapy

    Time frame: 6 and 12 Weeks

07

Results

Posted Jul 4, 2011

Participant flow

A total of 1044 patients (adult male and non-pregnant females) were enrolled at 122 Canadian family practice sites between May 2008 and May 2009. Out of these, only 598 patients were allocated to treatment. The remaining 446 did not receive treatment as they did not fulfill the inclusion/exclusion criteria.

Participant flow — Overall Study
MilestoneRosuvastatin TitratedRosuvastatin Non-titrated
Started154444
Completed153401
Not completed143
Withdrew: Adverse event015
Withdrew: Lost to follow-up010
Withdrew: Withdrawal by subject06
Withdrew: Did not receive treatment01
Withdrew: Incorrect enrollment06
Withdrew: Severe non-compliance to protocol01
Withdrew: Not reported14

Outcome measures

PrimaryPercentage of Subjects Achieving Canadian Low Density Lipoprotein Cholesterol (LDL-C) Target Goals (i.e. LDL-C ≤ 2.0 mmol/L) After 12 Weeks of Rosuvastatin Therapy

The number of subjects achieving Canadian Low density lipoprotein cholesterol (LDL-C) target goals (i.e. LDL-C ≤ 2.0 mmol/L) over the total number subjects treated after 12 weeks of rosuvastatin therapy multiplied by 100

Time frame:
12 Weeks
Reported as:
Mean · Percentage
Percentage of Subjects Achieving Canadian Low Density Lipoprotein Cholesterol (LDL-C) Target Goals (i.e. LDL-C ≤ 2.0 mmol/L) After 12 Weeks of Rosuvastatin Therapy
PercentageRosuvastatin 10 mg (Initial)Rosuvastatin 20 mg (Initial)Rosuvastatin 20 mg (Titrated)Rosuvastatin 40 mg (Titrated)
Percentage of Subjects Achieving Canadian Low Density Lipoprotein Cholesterol (LDL-C) Target Goals (i.e. LDL-C ≤ 2.0 mmol/L) After 12 Weeks of Rosuvastatin Therapy87 ± 8287 ± 8176 ± 6563 ± 52
SecondaryPercentage of Subjects Achieving Total Cholesterol (TC)/ High-density Lipoprotein Cholesterol (HDLC) Ratio (i.e. TC/HDL < 4.0 mmol/L) at 6 and 12 Weeks of Treatment

Proportion of subjects achieving total cholesterol (TC)/ High-density lipoprotein cholesterol (HDLC) ratio (i.e. TC/HDL \< 4.0 mmol/L) at 6 and 12 weeks of treatment

Time frame:
6 and 12 Weeks
Reported as:
Mean · Percentage of participants

Results for this outcome have not been posted.

SecondaryMean Percent Change in Total Cholesterol (TC), Low Density Lipoprotein Cholesterol (LDL-C), High-density Lipoprotein Cholesterol (HDLC) , TC/HDL-C Ratio, Non-HDL-C, Triglycerides and Apolipoprotein B (ApoB) /Apolipoprotein A1 (ApoA-1) Ratio
Time frame:
6 and 12 Weeks
Reported as:
Mean · Percentage

Results for this outcome have not been posted.

SecondaryMean High Sensitivity C-reactive Protein (hsCRP) Value at Week 6 and 12
Time frame:
6 and 12 Weeks
Reported as:
Mean · value mg/L

Results for this outcome have not been posted.

SecondaryIncidence of Adverse Events and Abnormal Laboratory Values After 12 Weeks of Therapy
Time frame:
6 and 12 Weeks
Reported as:
Number · Participants

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin 10 mg (Initial)—4/319 (1.3%)14/319 (4.4%)
Rosuvastatin 10 mg (Continued, Non-titrated)—2/232 (0.9%)4/232 (1.7%)
Rosuvastatin 20 mg (Initial)—0/279 (0%)9/279 (3.2%)
Rosuvastatin 20 mg (Continued, Non-titrated)—0/182 (0%)3/182 (1.6%)
Rosuvastatin 20 mg (Titrated)—1/75 (1.3%)2/75 (2.7%)
Rosuvastatin 40 mg (Titrated)—1/78 (1.3%)0/78 (0%)
Most frequent serious events
Most frequent serious events
EventRosuvastatin 10 mg (Initial)Rosuvastatin 10 mg (Continued, Non-titrated)Rosuvastatin 20 mg (Initial)Rosuvastatin 20 mg (Continued, Non-titrated)Rosuvastatin 20 mg (Titrated)Rosuvastatin 40 mg (Titrated)
CellulitisSkin and subcutaneous tissue disorders0/3190/2320/2790/1821/750/78
Aortic Aneurysm RuptureCardiac disorders0/3190/2320/2790/1820/751/78
LabyrinthitisEar and labyrinth disorders0/3191/2320/2790/1820/750/78
Chemical PoisoningInjury, poisoning and procedural complications0/3191/2320/2790/1820/750/78
Renal ColicRenal and urinary disorders1/3190/2320/2790/1820/750/78
Urinary Tract InfectionRenal and urinary disorders1/3190/2320/2790/1820/750/78
Cerebrovascular AccidentNervous system disorders1/3190/2320/2790/1820/750/78
Urinary RetentionRenal and urinary disorders1/3190/2320/2790/1820/750/78
Most frequent other events
Most frequent other events
EventRosuvastatin 10 mg (Initial)Rosuvastatin 10 mg (Continued, Non-titrated)Rosuvastatin 20 mg (Initial)Rosuvastatin 20 mg (Continued, Non-titrated)Rosuvastatin 20 mg (Titrated)Rosuvastatin 40 mg (Titrated)
BronchitisRespiratory, thoracic and mediastinal disorders2/3193/2321/2790/1822/750/78
CoughRespiratory, thoracic and mediastinal disorders7/3191/2322/2791/1820/750/78
ConstipationGastrointestinal disorders5/3190/2326/2792/1820/750/78

Baseline characteristics

Age Continuous
Age Continuous(Years)Rosuvastatin 10 mg (Initial)Rosuvastatin 20 mg (Initial)Total
Mean63.2 ± 10.962.6 ± 10.562.9 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin 10 mg (Initial)Rosuvastatin 20 mg (Initial)Total
Female150145295
Male169134303
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rosuvastatin 10 mg (Initial)Rosuvastatin 20 mg (Initial)Total
White288245533
Black/African American5712
Asian221739
Other41014
Body Mass Index
Body Mass Index(kg/m^2)Rosuvastatin 10 mg (Initial)Rosuvastatin 20 mg (Initial)Total
BMI32.50 ± 6.8932.27 ± 6.7232.39 ± 6.81
Waistline circumference
Waistline circumference(cm)Rosuvastatin 10 mg (Initial)Rosuvastatin 20 mg (Initial)Total
Mean106.7 ± 14.9106.7 ± 15.9106.7 ± 15.4
08

Study locations

84 sites
  • Research Site
    Calgary, Alberta, Canada
  • Research Site
    Edmonton, Alberta, Canada
  • Research Site
    Red Deer, Alberta, Canada
  • Research Site
    Spruce Grove, Alberta, Canada
  • Research Site
    St Albert, Alberta, Canada
  • Research Site
    Chilliwack, British Columbia, Canada
  • Research Site
    Coquitlam, British Columbia, Canada
  • Research Site
    Delta, British Columbia, Canada
  • Research Site
    Kelowna, British Columbia, Canada
  • Research Site
    Maple Ridge, British Columbia, Canada
  • Research Site
    Penticton, British Columbia, Canada
  • Research Site
    Victoria, British Columbia, Canada
  • Research Site
    Portage La Prairie, Manitoba, Canada
  • Research Site
    Winnipeg, Manitoba, Canada
  • Research Site
    Bathurst, New Brunswick, Canada
  • Research Site
    Woodstock, New Brunswick, Canada
  • Research Site
    Carbonear, Newfoundland and Labrador, Canada
  • Research Site
    Mount Pearl, Newfoundland and Labrador, Canada
  • Research Site
    St John's, Newfoundland and Labrador, Canada
  • Research Site
    Halifax, Nova Scotia, Canada
  • Research Site
    Kentville, Nova Scotia, Canada
  • Research Site
    Pubnico, Nova Scotia, Canada
  • Research Site
    Sydney Mines, Nova Scotia, Canada
  • Research Site
    Truro, Nova Scotia, Canada
  • Research Site
    Aylmer, Ontario, Canada
  • Research Site
    Bolton, Ontario, Canada
  • Research Site
    Chatham, Ontario, Canada
  • Research Site
    Fort Erie, Ontario, Canada
  • Research Site
    Georgetown, Ontario, Canada
  • Research Site
    Hamilton, Ontario, Canada
  • Research Site
    Kingston, Ontario, Canada
  • Research Site
    Kitchener, Ontario, Canada
  • Research Site
    London, Ontario, Canada
  • Research Site
    Mississauga, Ontario, Canada
  • Research Site
    Morrisburg, Ontario, Canada
  • Research Site
    Nepean, Ontario, Canada
  • Research Site
    Newmarket, Ontario, Canada
  • Research Site
    North York, Ontario, Canada
  • Research Site
    Oshawa, Ontario, Canada
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Scaborough, Ontario, Canada
  • Research Site
    Scarborough, Ontario, Canada
  • Research Site
    Smith Falls, Ontario, Canada
  • Research Site
    St Catherines, Ontario, Canada
  • Research Site
    St. Catharines, Ontario, Canada
  • Research Site
    Sudbury, Ontario, Canada
  • Research Site
    Thornhill, Ontario, Canada
  • Research Site
    Thorold, Ontario, Canada
  • Research Site
    Thunder Bay, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Welland, Ontario, Canada
  • Research Site
    Willowdale, Ontario, Canada
  • Research Site
    Windsor, Ontario, Canada
  • Research Site
    Woodstock, Ontario, Canada
  • Research Site
    Charlottetown, Prince Edward Island, Canada
  • Research Site
    Kensington, Prince Edward Island, Canada
  • Research Site
    Montague, Prince Edward Island, Canada
  • Research Site
    Anjou, Quebec, Canada
  • Research Site
    Dolbeau-mistassini, Quebec, Canada
  • Research Site
    Drummondville, Quebec, Canada
  • Research Site
    Forestville, Quebec, Canada
  • Research Site
    Gatineau, Quebec, Canada
  • Research Site
    Joliette, Quebec, Canada
  • Research Site
    L'ile- Perrot, Quebec, Canada
  • Research Site
    La Sarre, Quebec, Canada
  • Research Site
    Laval, Quebec, Canada
  • Research Site
    Longueuil, Quebec, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Roberval, Quebec, Canada
  • Research Site
    Roxton Pond, Quebec, Canada
  • Research Site
    Saint-bruno-lac-saint-jean, Quebec, Canada
  • Research Site
    Saint-charles-borromee, Quebec, Canada
  • Research Site
    Saint-leonard, Quebec, Canada
  • Research Site
    Saint-marc-des-carrieres, Quebec, Canada
  • Research Site
    Saint-pie, Quebec, Canada
  • Research Site
    Sainte Gedeon-de-beauce, Quebec, Canada
  • Research Site
    Sherbrooke, Quebec, Canada
  • Research Site
    Thetford Mines, Quebec, Canada
  • Research Site
    Trois-rivieres, Quebec, Canada
  • Research Site
    Moose Jaw, Saskatchewan, Canada
  • Research Site
    Porcupine Plain, Saskatchewan, Canada
  • Research Site
    Saskatoon, Saskatchewan, Canada
  • Research Site
    Yorkton, Saskatchewan, Canada
  • Research Site
    Quebec, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2008
First posted
Sep 4, 2008
Start
May 2008
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Jul 4, 2011
Last update
Aug 31, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00747149
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 4, 2008
Start date
May 2008
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Jul 4, 2011
Last update
Aug 31, 2011

Study contacts

Davide Meani
study director · AstraZeneca
David Lau, MD
principal investigator · Private Practice

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion